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ABSTRACT 
The insulin like growth factor-II/mannose-6-phosphate (IGF-II/ 
M6P) receptor has been detected in many cells and tissues. In the rat, 
there is a dramatic developmental regulation of IGF-II/MGP receptor 
expression, the receptor being high in fetal and neonatal tissues and 
declining thereafter. We have systematically studied the expression of 
the human IGF-II/MGP receptor protein in tissues from 10 human 
fetuses and infants (age 23 weeks gestation to 24 months postnatal). 
We have asked 1) whether there is differential expression among 
different organs, and 2) whether or not the human IGF-II/MGP recep- 
tor is developmentally regulated from 23 weeks gestation to 24 months 
postnatal. Protein was extracted from human tissues using a buffer 
containing 2% sodium dodecyl sulfate and 2% Triton X-100. Aliquots 
of the protein extracts were analyzed by sodium dodecyl sulfate-poly- 
acrylamide gel electrophoresis and immunoblotting using an anti-IGF- 
II/MGP receptor antiserum (no. 66416) and lz51-protein A or an im- 
munoperoxidase stain. IGF-II/MGP receptor immunoreactivity was 
detected in all tissues studied with the highest amount of receptor 
being expressed in heart, thymus, and kidney and the lowest receptor 
content being measured in brain and muscle. The receptor content in 
ovary, testis, lung, and spleen was intermediate. The apparent molec- 
ular weight of the IGF-II/MGP receptor (220,000 kilos without reduc- 
tion of disulfide bonds) varied among the different tissues: in brain the 
receptor was of lower molecular weight than in other organs. Immun- 
oquantitation experiments employing Y-protein A and protein ex- 
tracts from human kidney at different ages revealed a small, albeit not 
significant, difference of the receptor content between fetal and post- 
natal tissues: as in other species, larger amounts of receptor seemed to 
be present in fetal than in postnatal organs. In addition, no significant 
difference of the receptor content between human fetal liver and early 
postnatal liver was measured employing Y-protein A-immunoquan- 
titation in three fetal and five postnatal liver tissue samples. The 
distribution of IGF-binding protein (IGEBP) species, another abun- 
dant and major class of IGF binding principles, was also measured in 
human fetal and early postnatal lung, liver, kidney, muscle, and brain 
using Western ligand blotting with ‘251-IGF-II: as with IGF-II/MGP 
receptor immunoreactivity there was differential expression of the 
different classes of IGFBPs in the various organs. In conclusion, 1) the 
IGF-II/MGP receptor is present in multipie human tissues, 2) the 
human IGF-II/MGP recentor is variablv exnressed in different organs, 
3) there is a m&h lesser degree of developmental regulation of IGF-II/ 
M6P receptor expression in the human than has been reported for the 
rat or sheep, 4) the differential pattern of distribution of IGF-II/MGP 
receptor and IGFBPs in the various organs throughout fetal and early 
postnatal human life points to an important and tissue specific role of 
the IGF binding principles in development and growth. (J Clin Endo- 
crinol Metab 75: 424-431,1992) 
T HE insulin-like growth factor-II (IGF-II) is a polypeptide which belongs to the insulin family of polypeptide hor- 
mones that also includes IGF-I and relaxin (l-3). Although 
the aminoacid sequence and molecular structure of IGF-II 
have long been characterized (4, 5), its biological action and 
physiological role in viva are still elusive: 1) it has been 
suggested that IGF-II plays a role in the growth and devel- 
opment of the central nervous system and of certain tumors 
(6-9). 2) Alternatively, IGF-II might be involved in fetal 
growth and development, since both serum IGF-II levels and 
tissue IGF-II messenger RNA content are high prenatally and 
decline after birth. Although this is true in mice, rats, and 
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sheep (lo-14), in the human, IGF-II levels are lower during 
prenatal life and do not change dramatically after birth (15- 
18). 3) Recently, IGF-II has been implicated in modulating 
the cellular uptake of lysosomal enzymes via the IGF-II/ 
mannose-6-phosphate (M6P) receptor (19-22). It is hypoth- 
esized that a growth factor, IGF-II, might thus be a regulator 
of the major degradative pathway of the cell. IGF-II binds to 
two high affinity receptors which are present in many cells 
and tissues. The IGF-I receptor prefers IGF-I over IGF-II and 
also binds insulin. This receptor resembles the insulin recep- 
tor and contains tyrosine kinase activity (1, 2, 23, 24). It is 
thought that the IGF-I receptor mediates the metabolic and 
growth promoting action of the IGFs (25-27). The IGF-II 
receptor binds IGF-II with high affinity, recognizes IGF-I 
only weakly, and does not bind insulin at all. This receptor 
does not have intrinsic tyrosine kinase activity (24, 28). 
Interestingly, the IGF-II receptor has been shown by com- 
plementary DNA cloning to be identical to the cation-inde- 
pendent M6P receptor (29-31). These observations were 
confirmed by biochemical and immunological studies (32- 
36). The M6P receptor functions to target lysosomal enzymes 
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bearing the M6P recognition marker to lysosomes (37-39). 
In addition, a signaling role for the IGF-II/M6P receptor has 
been suggested by some authors (40-45). A truncated form 
of the IGF-II/M6P receptor lacking the cytoplasmic domain 
of the membrane receptor molecule has been identified in 
the circulation in many species (46-48). It has been hypoth- 
esized that the process of proteolytic cleavage that leads to 
the production of the serum form of the IGF-II/M6P receptor 
serves as a major degradative pathway for the receptor (49). 
Recently, the levels of IGF-II/M6P receptor protein in rat, 
sheep, and monkey serum and tissue have been measured 
(46, 47, 50, 51). In this study, we measured by immunoblot- 
ting the IGF-II/M6P receptor protein content in solubilized 
whole tissue extracts from human fetuses and infants ranging 
in age from 23 weeks before to 24 months after birth. 
Immunoblots were analyzed to determine if there is differ- 
ential expression of the IGF-II/M6P receptor among different 
human tissues and whether or not there exists a develop- 
mental regulation of receptor protein expression in the hu- 
man. Ligand blotting employing ‘251-IGF-II as the radioligand 
was used to compare the organ distribution of IGF-binding 
protein (IGFBP) species with that of the IGF-II/M6P receptor. 
Subjects and Methods 
Tissue collection 
Tissues (kidney, brain, liver, lung, testis, ovary, spleen, thymus, 
muscle, heart) were collected from 10 aborted or stillborn fetuses and 
infants who had died suddenly (sudden infant death syndrome) or by 
accident. The time interval between death and removal of tissues at the 
Institutes of Forensic Medicine and Pathology, University of Munich, 
Munich, Germany, was between 4 and approximately 24 h. Tissues 
were removed aseptically, diced, and immediately frozen in liquid 
nitrogen. The study protocol had been approved by the Ethical Com- 
mittee of the Children’s Hospital (University of Munich, Munich, Ger- 
many). 
Tissue extraction 
Approximately 20 mg thawed tissue were placed in 1.5 mL plastic 
tubes and weighed; 0.4 mL 20 mmol Tris, 2% Triton X-100, pH 7.4, and 
0.1 mL Laemmli buffer containing 2% sodium dodecyl sulfate (SDS) 
(49) was added, and the tissues homogenized for 3 min with a Polytron 
homogenizer (Polytron PT 10-35, Bachofer, Reutlingen, Germany). The 
samples were boiled for 5 min and then incubated overnight at 4 C. The 
protein homogenates were then boiled again for 1 min and centrifuged 
for 5 min at 10,000 X gin a Mikrorapid/K centrifuge (Hettich, Tuttlingen, 
Germany). No visible pellet was seen after extraction. Aliquots of the 
supernatants were stored at -20 C until further analysis. The protein 
content of the tissue extracts was determined using the BCA protein 
assay (Pierce Chemical Co., Rockford, IL, Cat. no. 23225). Dilutions of 
BSA were used as protein standards. 
Immunoblotting 
Aliquots of the tissue extracts amounting to 0.2 mg protein per organ 
examined were subjected to SDS-polyacrylamide gel electrophoresis 
(PAGE) under nonreducing conditions using the discontinuous buffer 
system of Laemmli (52). Prestained molecular weight markers were used 
as follows: lysozyme, 14,300; P-lactoglobulin, 18,400; carbonic anhy- 
drase, 29,000; ovalbumin, 43,000; BSA, 68,000; phosphorylase B, 
97,400; myosin, 200,000 (BRL, Eggenstein, Germany, prestained protein 
molecular weight standards, Cat. no. 6041LA). The electrophoresed 
samples were transferred onto nitrocellulose (Schleicher & Schuell, 
Dassel, Germany, Cat. no. 401180) by electroelution (500 mA; 8OV), 
and stained using 0.1% Fast Green (Merck, Darmstadt, Germany, Cat. 
no. 4022) in 1% acetic acid. After destaining in 0.01 molar NaOH, 
immunoblotting was performed using a specific antiserum against the 
human IGF-II/MGP receptor (no. 66416, a kind gift from Dr. W. Sly, St. 
Louis, MO) following an earlier described protocol (50). The antiserum 
was used at a final dilution of 1:2000. An immunoperoxidase staining 
kit (Vectastain ABC kit, Vector Laboratories, Inc., Burlingame, CA) was 
used to detect specific protein bands on the nitrocellulose filters employ- 
ing horse radish peroxidase and an avidin-biotin enhancing step. After 
drying overnight, the nitrocellulose sheets were photographed. 
Zmmunoqzuxntitation 
In order to estimate the variation between samples (organs from 
different fetuses or infants) and to analyze the variation of the measuring 
technique (immunoblotting), the relative IGF-II/M6P receptor content 
of protein extracts from two organs with high/intermediate receptor 
content (liver and kidney) was quantitated. Immunoblotting was per- 
formed using antiserum 66416 and ?-protein A according to Sklar et 
al. (50). After drying overnight, the nitrocellulose sheets were autoraci- 
ographed using Kodak X-AR film (X-Omat AR, no. 150, 1451, Kodak, 
Rochester, NY) and enhancing screens (Du Pont, New England Nuclear, 
Boston, MA) at -70 C. The specific receptor bands detected on x-ray 
films were cut out from the nitrocellulose filters and were counted in a 
y-counter (Berthold, LB 2103, Munich, Germany). The results of three 
independent experiments (three independent extractions from the same 
organ of three human fetuses (gestational age 23, 35, and 41 weeks) 
and of four (kidney) and, respectively, five (liver) infants (3, 4, 13, 18, 
and 24 months postnatal) were analyzed using Student’s t test. Values 
for fetal tissue receptor content were compared with those of postnatal 
tissue receptor content. 
Western ligand blotting 
Aliquots (200 rg) of the tissue extracts were subjected to SDS-PAGE 
(12.5% acrylamide-bis) under nonreducing conditions as described by 
Laemmli (52). Proteins were then transferred onto nitrocellulose filters 
by electroelution as described for the immunoblotting procedure. Ligand 
blotting was then carried out essentially as described by Hossenlopp et 
nl. (53). In brief, the nitrocellulose filters were blocked in buffer contain- 
ing 1% BSA, and subsequently incubated with ‘251-IGF-II (Amersham, 
Braunschweig, Germany) diluted in 0.15 mol NaCl, 10 mmol Tris-HCl, 
1% BSA, 0.1% Tween-20, pH 7.4 (20 ml/filter/bag) in the presence or 
absence of 2 rg/mL unlabeled human recombinant IGF-II (a kind gift 
from Dr. A. Skottner, Stockholm, Sweden) for 12 h at 4 C temperature. 
The nitrocellulose sheets were then washed extensively in a 0.15 mol 
NaCl, 10 mmol Tris-HCl, 0.1% Tween-20, pH 7.4 buffer, and finally in 
a 0.15 mol NaCl, 10 mmol Tris-HCl, pH 7.4 buffer, and dried overnight. 
Autoradiographs were obtained by exposing the filters to Kodak-X- 
Omat films (Eastman Kodak) using enhancer screens (DuPont, Newton, 
CT) at -70 C. 
Results 
Specificity of immunodetection of IGF-IIjM6P receptors in 
human tissues 
When protein extracts from human lung tissues were 
immunoblotted using anti-IGF-II/M6P receptor antiserum 
66416, a single band at approximately 220 kilos mol wt 
corresponding to the approximate molecular weight of the 
IGF-II/M6P receptor upon SDS-PAGE was detected on the 
nitrocellulose sheets and no other band was stained (Fig. 1). 
When control serum from normal rabbit was used instead of 
the antiserum no protein band was detected (data not 
shown). The specific receptor band was found in all lung 
tissues examined irrespective of the age of the donor: it was 
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FIG. 1. Immunoblotting of protein ex- 
tracts from human lung. Approximately 
200 pg protein extracts were analyzed by 
SDS-PAGE. Proteins were transferred 
by electroelution to nitrocellulose sheets, 
and the sheets were incubated succes- 
sively with anti-IGF-II/MGP receptor 
antiserum and an immunoperoxidase 
stain as described in Subjects and Meth- 
ods. The arrow points to the specific 220- 
kDa receptor band. Lung protein ex- 
tracts from four fetuses and five infants 
were analyzed. 
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present at 23, 26, 35, and 41 weeks gestational age, and 3, 
4,13, 18, and 24 months postnatal. In contrast, when protein 
extracts from human kidney were examined by immuno- 
blotting, not only the 220-kilodalton (kDa) receptor band 
was stained but also protein bands at 140 and at 72, 77, and 
82 kDa were detected (Fig. 2A): the latter species were also 
seen when human kidney proteins were analyzed using 
control rabbit serum instead of the antireceptor antiserum 
(Fig. 2B). These proteins were also seen on blots when only 
the avidin horse radish peroxidase complex was added with- 
out prior exposure of the nitrocellulose sheets to any serum 
and/or biotinylated second antibody (data not shown). In 
addition, these bands had no peroxidase activity as shown 
by enzymatic testing using 4-chloro-a-naphtol as staining 
reagent and H202 as substrate (data not shown). These results 
suggest that the immunostaining procedure used in these 
experiments detects biotinylated proteins which are present 
in some (kidney, liver, muscle) but not in other (lung, brain) 
human organs. The anti-IGF-II/MbP receptor antiserum used 
throughout these experiments, however, is specific for the 
human IGF-II/M6P receptor as has been described originally 
(31). As in lung tissue, the IGF-II/MGP receptor band at an 
approximate molecular weight of 220 kilos was present in 
kidney tissues at all ages examined: it was seen in kidney 
extracts from 23,26, and 41 weeks gestation fetuses and also 
from infants of 3,4, 13, 18, and 24 month postnatal age (Fig. 
2A). 
Immunodetection of IGF-II/M6P receptor protein-variable 
expression of the receptor in multiple human tissues 
When tissue extracts of heart, psoatic muscle, lung, kidney, 
liver, brain, testis, ovary, spleen, and thymus from 10 human 
fetuses and infants were analyzed for IGF-II/M6P receptor 
content, all organs examined contained detectable amounts 
of receptor protein (Fig. 3, A, B, C). Three representative 
JCE & M l 1992 
Vol75.No2 
Mr x 10m3 
220 
110 
72 
26 35 41 - - - - - 
- - - 3 4 13 18 24 
immunoblots showing the analysis of tissue extracts from 
one fetus (25 weeks gestation) or infant (3- and 13-month 
postnatal age) respectively, are shown (Fig. 3, A, B, C). The 
apparent molecular weight of the receptor band varied 
among the organs studied: generally, the receptor in brain 
was of lower molecular weight than the IGF-II/M6P receptor 
species in the remaining eight tissues. In some organs (thy- 
mus, liver, lung, ovary, spleen) doublet bands were occasion- 
ally detected (Figs. 3 and 4). The amount of immunoreactivity 
measured in the different organs varied considerably. How- 
ever, when the organs were grouped according to their IGF- 
II/M6P receptor content as estimated from 10 immunoblots, 
heart, thymus, and kidney consistently contained the highest 
amount of IGF-II/M6P receptor immunoreactivity whereas 
brain and muscle expressed the lowest level of IGF-II/MBP 
receptor immunoreactivity. The receptor content in ovary, 
testis, liver, lung, and spleen was intermediate (Table 1). 
Immunoquantitation of IGF-II/MBP receptor 
expression during human fetal life and early infancy 
The putative developmental regulation of IGF-II/M6P re- 
ceptor expression was studied by immunoblotting tissue ex- 
tracts from the same organ of donors of different ages: when 
protein extracts of lung, liver, kidney, thymus, and heart 
from human fetuses (23,26,35, and 41 weeks gestation) and 
infants (3, 4, 13, 18, and 24 months of age) were subjected 
to SDS-PAGE and immunoblotted using the specific anti- 
IGF-II/M6P receptor antiserum 66416, the receptor protein 
was again found in all organs and at all ages examined: there 
was considerable variation of the amount of receptor protein 
as measured by immunoblotting between ages. However, 
there was no clear and consistent pattern of variation which 
would have indicated a developmental regulation of receptor 
expression in the human between 23 weeks of gestation and 
24 months postnatal (Fig. 4). In addition, no sex difference 
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FIG. 2. Immunoblots of protein extracts from human kidney. Immu- 
noblotting was performed as in Fig. 1. A, Anti-IGF-II/MGP receptor 
antiserum and an immunoperoxidase stain were applied; B, control 
rabbit serum and the immunoperoxidase stain were used. The arrow 
points to the IGF-II/MGP receptor band. Kidney protein extracts from 
three fetuses and five infants were analyzed. The nonspecific protein 
bands presumably represent biotinylated enzymes which are expressed 
in kidney. 
of receptor expression was apparent (data not shown). To 
quantitate the relative amount of IGF-II/M6P receptor pro- 
tein in human kidney and liver at different age points further, 
immunoblotting was performed using lz51-protein A and 
autoradiography for visualization of receptor species. Specific 
receptor bands were then cut out from the nitrocellulose 
sheets and radioactivity counted in a y-counter. Again, there 
was considerable variation in receptor content of the same 
sample between experiments. More importantly, receptor 
content of different samples also varied greatly. In kidney, 
receptor content was apparently higher in samples that were 
obtained from fetuses than in postnatal samples. However, 
when statistical analysis of relative receptor content at dif- 
ferent ages was performed, comparing three prenatal samples 
with four postnatal samples, no statistically significant dif- 
ference was found (Table 2). In addition, no significant 
difference of IGF-II/M6P receptor content between three 
fetal and five postnatal liver samples was detected (Table 2). 
Detection of tissue-specific expression of IGFBPs in multiple 
human tissues by Western ligand blotting with lz51GF-II 
To compare the variable expression of the IGF-II/M6P 
receptor protein in different tissues with the presence of 
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FIG. 3. Immunoblots from tissue extracts (same age, different tissues). 
Immunoblotting was performed as described in Fig. 1. A, 25 weeks 
gestation; B, 3 months postnatal; C, 13 months postnatal. 
multiple IGFBP species in the same organs, protein extracts 
from five different human tissues (psoatic muscle, brain, 
liver, lung, and kidney) were analyzed by SDS-PAGE and 
ligand blotting using 1251-IGF-II. Five distinct radiolabeled 
protein species with an approximate molecular weight of 43, 
38, 34, 30, and 20 kilos, respectively, were detected (Fig. 5). 
The intensity of the radiolabeled bands varied among the 
tissues studied: in brain, the 34-kDa band was predominant, 
while in psoatic muscle, the 30-kDa species was the major 
band as seen in seven ligand blotting experiments using 
tissue samples from eight fetuses and infants. The apparent 
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FIG. 4. Immunoblots from tissue extracts (different age, same tissue). 
Immunoblotting was performed as described in Subjects and Methods. 
Protein extracts (200 rg) were applied to each lane. The 220-kDa 
receptor bands from each organ are shown in a representative manner 
for four fetuses and five infants. 
TABLE 1. IGF-II/MGP receptor content of human tissues (10 
subjects, 23 weeks gestation to 24 months postnatal) 
Low Intermediate High 
Organs with low receptor 
content 
Brain n=5 n=3 0 
Psoatic muscle n=6 n=l 0 
Organs with intermediate re- 
ceptor content 
Ovary/testis 0 n=8 0 
Liver n=l n=6 n=3 
Lung n=3 n=5 0 
Spleen n=l n=5 n=2 
Organs with high receptor 
content 
Heart n=l n=3 n=4 
Kidney n=l n=2 n=7 
Thymus n=l n=l n=8 
molecular weight of the IGFBP species found in human 
tissues by ligand blotting experiments corresponds well with 
the molecular weight of IGFBP species commonly detected 
in human plasma and serum. The tissue distribution of the 
IGFBPs cannot be explained by differential degradation in 
the various organs nor by contamination of the tissues by 
blood. A more detailed analysis of the expression of IGFBP 
species in human tissues has been carried out (Funk, B., U. 
Kessler, W. Kiess, manuscript submitted). 
The IGF-II/M6P-receptor is present in many tissues in rats, 
mice, and sheep (24, 47, 50, 54). The IGF-II/M6P receptor 
Vol75.No2 
TABLE 2. Immunoreactivity of IGF-II/MGP receptor in human 
kidney and liver as measured by immunoblotting and lz51-protein A 
quantitation 
Gestational age 
(weeks) Postnatal age (months) 
23 35 41 3 4 18 24 
Kidney 
415 505 472 546 253 163 95 
317 202 524 415 47 112 87 
463 f  108” 2672 75 
Mean + SEM 
Gestational age 
(weeks) Postnatal age (months) 
26 35 41 3 4 13 18 24 
Liver 
93 266 476 455 374 76 364 37 
74 283 546 535 369 18 382 11 
278 -t117 262 + 87 
Mean + SEM 
Values are means f  SEM of triplicate mf%SUre?nentS of COUntS per 
min (9-protein A per 220 kDa receptor lane). 
“Receptor content of prenatal tissues does not differ significantly 
from receptor content of postnatal tissues. 
has also been found on many cells including cell lines from 
human origin (24,37) and in human brain, liver, and placenta 
(1, 2, 54). In this study, we have measured the receptor in 
solubilized whole tissue extracts from human fetuses and 
infants ranging in age from 23 weeks gestation to 2 yr 
postnatal. IGF-II/M6P receptor immunoreactivity was pres- 
ent in all tissues examined (brain, kidney, liver, lung, heart, 
testis, ovary, thymus, and spleen). As in the rat (50), brain 
contained the lowest concentration of IGF-II/M6P receptor 
protein, and heart and kidney consistently contained large 
amounts of receptor immunoreactivity. In addition, thymus 
also contained higher amounts of the receptor. Muscle, which 
contained high amounts of receptor protein in the rat, had 
only low receptor content in the human. The receptor content 
in ovary, testis, lung, and spleen was intermediate. As re- 
ported for the rat (50, 55), the human IGF-II/M6P receptor 
varied in size. Consistent with the results in the rat, the 
receptor in brain was smaller in size than that in other tissues. 
Presumably, this variation in receptor size reflects differential 
glycosylation of the receptor in the different tissues as has 
been suggested in the literature (55). Such variation in size 
also occurs during receptor synthesis in cells in culture (56, 
57). Immunoreactive receptor species of lower molecular 
weight could thus reflect receptor precursors and indicate 
tissues of high receptor turnover or receptor synthesis. Alter- 
natively, lower molecular weight receptor species could rep- 
resent degradation products in proteolytic tissues (37, 48). 
As with the IGF-II/M6P receptor protein there was also 
differential expression of IGFBP species in different organs: 
brain predominantly contained a 34-kDa IGFBP consistent 
with reports in the literature of the expression of such a 
specific 34-kDa IGFBP in cerebrospinal fluid (52). The dif- 
ferential expression of IGF-II/M6P receptors and IGFBP spe- 
cies in different human tissues points to specific biological 
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FIG. 5. Analysis of IGFBPs in protein 
extracts from human tissues. Proteins 
were extracted and analyzed by SDS- 
PAGE and ligand-blotting using iz61- 
IGF-II as described in Subjects and 
Methods. For comparison, 2 pL of human 
serum were also analyzed on each blot. 
The double arrow head points to the 43- 
kDa region, presumably representing the 
IGFBP-3 species, whereas the open ar- 
row indicates the position of the 30-kDa 
IGFBP predominantly expressed in 
muscle. The 34-kDa IGFBP in brain is 
indicated by a filled arrow head. 
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lu liv 
roles of the IGF binding moieties in the respective tissues 
and allows for modulation of IGF mediated biological effects 
in these organs. 
In the rat, a dramatic (up to loo-fold) difference in the 
amount of IGF-II/M6P receptor between fetal and postnatal 
serum (46) and tissues (50) has been reported. In sheep and 
monkey serum, developmental regulation of IGF-II/M6P 
receptor expression has also been suggested (47, 51). In the 
human, we have found only a minimal difference of receptor 
content between prenatal and postnatal kidney and no such 
difference in liver tissues (between 23 weeks gestation and 
24 months postnatal age). It is possible that the failure to 
detect a significant developmental regulation of receptor 
expression in the human was due to 1) autolytic processes 
which might affect different tissues at different ages in a 
differential manner. However, no signs of degradation (pro- 
tein smear, etc.) appeared on any of the immunoblots, and 
other nonreceptor related proteins (i.e. biotinylated enzymes) 
expressed a clear developmental pattern (Fig. 2). 2) Alterna- 
tively, a more pronounced developmental regulation of IGF- 
II/M6P receptor expression might occur much earlier (before 
23 weeks of gestation) in human life than in embryologically 
comparable stages of development in the rat. It is interesting 
to note that whereas in the rat not only the IGF-II/M6P 
receptor but also the ligand, i.e. IGF-II itself, are develop- 
mentally regulated, in the human both the amount of IGF-II 
(l-3) and of the IGF-II/M6P receptor (this study) are barely 
or only to a small extent regulated during fetal and early 
postnatal development. 3) Failure to detect a significant 
difference of receptor content between fetal and postnatal 
tissues might also be due to the large variation caused by the 
detection technique (immunoblots) (Table 2). However, 
when the receptor content of different organs was compared, 
a clear grouping of tissues with organs of high, intermediate, 
and low receptor content was evident. If a developmental 
pattern (fetal VS. postnatal) was as pronounced in the human 
as in other species (rat, sheep) (lOO-fold difference!), the 
relatively large variability of the technique and potential 
intersample variations would still not mask such a large 
difference. 
Since the IGF-II/M6P receptor is present in all tissues 
ky se IU liv ky mu br se 
J 
+ 
2g+ 
examined and at all ages tested we hypothesize that this 
receptor type is involved in general functions of development 
and metabolism. The variable amounts of receptor protein 
present in different organs at different times of development 
make the IGF-II/M6P receptor a likely candidate of regula- 
tory processes that might be involved in organ development, 
growth, and tissue remodeling. The receptor would add to 
the variability of IGF binding capacity in different tissues 
caused by the differential expression of IGFBP classes in the 
various organs. In addition, the IGF-II/M6P receptor binds 
two classes of ligands, namely, a growth factor, IGF-II, and 
a number of lysosomal enzymes bearing the mannose-6- 
phosphate recognition marker (29, 30). This latter function 
might also be of biological importance during development 
and in different tissues. The fact that the IGF-II/M6P receptor 
maintains-as demonstrated by receptor-ligand blotting 
(data not shown)-its function of binding IGF-II in all tissues 
examined, further points to an interconnected network of 
tissue degradation and growth processes that meet at the 
cellular level, i.e. at a common receptor site. 
Acknowledgments 
We are grateful to Drs. S. Peter Nissley and M. M. Sklar, Bethesda, 
MD, and K. von Figura, Gottingen, Germany, for many helpful sugges- 
tions. We wish to express our special gratitude to Dr. W. Sly, St. Louis, 
MO, for his generous gift of anti-IGF-II/M6P receptor antiserum and to 
Dr. H. P. Schwarz, Munich, Germany, for his continuous support. 
References 
1. Humbel R. 1990 Insulin-like growth factors I and II. Eur J Biochem. 
190:445-62. 
2. Rechler MM, Nissley SP. 1990 Insulin-like growth factors. In: 
Spom MB, Roberts AB, eds. Peptide growth factors and their recep- 
tors. I. Handbook of pharmacology. Heidelberg, New York: Springer 
Publisher; 263-367. 
3. Daughaday WH, Rotwein P. 1989 Insulin-like growth factors/ 
somatomedins. Peptide, mRNA and gene structures, serum, and 
tissue concentrations. Endocr Rev. 10:68-90. 
4. Rinderknecht E, Humbel RE. 1978 Primary structure of human 
IGF-II. FEBS Lett. 89:283-6. 
5. Marquard H, Todaro GJ, Henderson LE, Oroszlan S. 1981 Purifi- 
cation and primary structure of a polypeptide with multiplication- 
 at UBM Klinikum Innenstadt on November 14, 2008 jcem.endojournals.orgDownloaded from 
430 FUNK 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
16. 
17. 
18. 
19. 
20 
21 
22 
23 
24 
25. 
26. 
27. 
stimulating activity from rat liver cell cultures. J Biol Chem. 
256:6859-65. 
Hasselbacher G, Irminger JC, Zapf J, Ziegler WH, Humbel RE. 
1987 IGF-II in human adrenal pheochromocytomoas and Wilms 
tumors: expression at the mRNA and protein level. Proc Nat1 Acad 
Sci USA. 84:1104-6. 
Ron D, Powers AC, Pandian MR, Godine JE, Axelrod L. 1989 
Increased IGF-II production and consequent suppression of GH 
secretion: a dual mechanism for tumor induced hypoglycemia. J 
Clin Endocrinol Metab. 68:701-6. 
Daughaday WH, Kapadia M. 1989 Significance of abnormal serum 
binding of IGF-II in the development of hypoglycemia in patients 
with non-islet-cell tumors. Proc Nat1 Acad Sci USA. 86:6778-82. 
Daughaday WH. 1990 Editorial: the possible autocrine/paracrine 
and endocrine roles of IGFs of human tumors. Endocrinology. 
127:1-4. 
Adams SO, Nissley SP, Greenstein LA, Yang YW-H, Rechler 
MM. 1983 Synthesis of MSA (rat IGF-II) by rat embryo fibroblasts. 
Endocrinology 112:979-87. 
Romanus JA, Yang YW, Adams SO, et al. 1988 Synthesis of IGF- 
II in fetal rat tissues: translation of IGF-II RNA and processing of 
pre-pro-IGF-II. Endocrinology. 122:709-16. 
Lund PK, Moats-Staats BM, Hynes MA, et al. 1986 IGF-I and -11 
mRNAs in rat fetal and adult tissues, J Biol Chem. 261:14539. 
Moses AC, Nissley SP, Cohen KL, Rechler MM. 1976 Specific 
binding of a somatomedin-like polypeptide in rat serum depends 
on GH. Nature. 263:137-40. 
Beck F, Samani NJ, Penschow JD, ThorIy B, Tregear GW, Coghlan 
JP. 1987 Histochemical localization of IGF-I and -11 mRNA in the 
developing rat embryo. Development. 101:175-84. 
Daughaday WH, Trivedi B, Kapadia M. 1981 Measurement of 
IGF-II by a specific RRA in serum of normal individuals, patients 
with abnormal GH secretion and patients with tumor associated 
hypoglycemia. J Clin Endocrinol Metab. 53:289-94. 
Zapf Walter H, Froesch ER. 1981 Radioimmunological determina- 
tion of IGF-I and -11 in normal subjects and in patients with growth 
disorders and extrapancreatic tumor hypoglycemia. J Clin Invest. 
68:1321-30. 
Furlanetto RW, Underwood LE, Van Wyk JJ, D’Ercole AJ. 1977 
Estimation of SM-C levels in normals and patients with pituitary 
disease by RIA. J Clin Invest, 60:638-57. 
Blum WF, Ranke MB, Bierich JR. 1988 A specific radioimmuno- 
assay for IGF-II: the interference of IGF binding proteins can be 
blocked by excess IGF-I. Acta Endocrinol (Copenh). 118:374-80. 
Kiess W, Thomas CL, Greenstein L, et al. 1989 IGF-II inhibits both 
the cellular uptake of beta-galactosidase and the binding of beta- 
galactosidase to purified IGF-II/M6P receptor. J Biol Chem. 
264:4710-4. 
Kiess W, Thomas CL, Sklar MM, Nissley SP. 1990 Beta-galacto- 
sidase decreases the binding affinity of the IGF-II/M6P receptor for 
IGF-II. Eur J Biochem. 190:71-7. 
Mathieu M, Rochefort H, Barenton B, Prebois C, Vignon F. 1990 
Interactions of cathepsin D and IGF-II on the IGF-II/M6P receptor 
in human breast cancer cells and possible consequences on mito- 
genie activity of IGF-II. Mol Endocrinol. 4:1327-35. 
Nolan CM, Kyle JW, Watanabe H, Sly WS. 1990 Binding of IGF- 
II by human cation-independent M6P/IGF-II receptor expressed in 
receptor-deficient mouse L cells. Cell Differ. 1:197-213. 
UIlrich A, Gray A, Tam AW, et al. 1986 IGF-I receptor primary 
structure: comparison with insulin receptor suggests structural de- 
terminants that define functional specificity. EMBO J. 5:2503-12. 
Rechler MM, NissIev SP. 1985 The nature and regulation of the 
receptors for IGFs. A&u Rev Physiol. 47:425-42. ” 
Kiess W, HaskelI JF, Lee L, et al. 1987 An antibody that blocks 
IGF binding to the type II IGF receptor is neither an agonist nor an 
inhibitor of IGF-stimulated biologic responses in L6 myoblasts. J 
Biol Chem. 262:12745-51. 
MottoIa C, Czech MP. 1984 The type II insulin-like growth factor 
receptor does not mediate increased DNA synthesis in H-35 hepa- 
toma cells, J Biol Chem. 259:12705-13. 
Furlanetto RW, DiCarlo JN, Wisehart C. 1987 The IGF-II receptor 
does not mediate DNA synthesis in human fibroblasts. J Clin 
ET AL. JCE & M. 1992 
Vol75’NoZ 
Endocrinol Metab. 64:1142-9. 
28. Corvera S, Whitehead RE, Mottola C, Czech MP. 1986 The IGF- 
II receptor is phosphorylated by a tyrosine kinase in adipocyte 
plasma membranes. J Biol Chem. 261:7675-9. 
29. Morgan DO, Erdman JC, Standring DN, et al. 1987 IGF-II receptor 
as a multifunctional binding protein. Nature. 329:301-7. 
30. MacDonald RG, Pfeffer SR, Coussens L, et al. 1988 A single 
receptor binds both IGF-II and mannose-6-phosphate. Science. 
239:1134-7. 
31. Oshima A, Nolan CM, Kyle JW, Gruff H, Sly WS. 1988 The 
human cation-independent M6P receptor. Cloning and sequence of 
the full-length cDNA and expression of functional receptors in cos 
cells. J Biol them. 263:2553-‘62. 
nn Tone PY. Tollefsen E. Kornfeld S. 1988 The cation-indeoendent 3‘. 
33. 
34. 
35. 
M6freceptor binds IGF-II. J Biol Chem. 263:2585-8. ’ 
Braulke T, Causin C, Waheed A, et al. 1988 M6P/lGF-11 receptor: 
distinct binding sites for mannose-6-phosphate and IGF-II. Biochem 
Biophys Res Commun. 150:1287-93. 
Polychronakos C, Guyda HJ, Posner BI. 1988 Mannose-6-phos- 
phate increases the affinity of its cation-independent receptor for 
IGF-11 by displacing inhibitory endogenous ligands. Biochem Bio- 
phys Res Commun. 157:632. 
Roth RA, Stover C, Hari J, Morgan DO, Smith MC, Sara V, Fried 
VA. 1987 Interactions of the receptor for IGF-II with M6l’ and 
antibodies to the M6P receptor. Biochem Biophys Res Commun. 
149:600-6. 
36. Kiess W, Blickenstaff GD, Sklar M, Thomas C, Nissley SP, 
Sahagian GG. 1988 Biochemical evidence that the type II IGF 
receptor is identical to the cation-independent M6P receptor. J Biol 
Chem. 263:9339-44. 
37. 
38. 
39. 
40. 
von Figura K, Hasilik A. 1986 Lyosomal enzymes and their recep- 
tors. Annu Rev Biochem. 55:167-93. 
Pfeffer SR. 1988 M6P receptors and their role in targeting proteins 
to lysosomes. J Membr Biol. 103:7-16. 
Dahms NM, Lobe1 P, Kornfeld S. 1989 M6P receptors and lyso- 
somal enzyme targeting. J Biol Chem. 264:12115-8. 
Tally M, Li CH, Hall K. 1987 IGF-II stimulated growth mediated 
by the somatomedin type II receptor. Biochem Biophys Res Com- 
mun. 148:811-6. 
41. 
42. 
43. 
44. 
Rogers SA, Hammerman MR. 1988 IGF-II stimulates production 
of inositol trisphosphate in proximal tubular basolateral membranes 
from dog kidney. Proc Nat1 Acad Sci USA. 85:4037-41. 
Bhaumick B, BaIa RM. 1988 Parallel effects of IGF-II and insulin 
on glucose metabolism of developing mouse embryonic limb buds 
in culture. Biochem Biophys Res Commun. 152:359-62. 
Okamoto T, Katada T, Murayama Y, Ui M, Ogata E, Nishimoto 
I. 1990 A simple structure encodes G protein-activating function of 
the IGF-II/mannose-6-phosphate receptor. Cell. 62:709. 
Hari J, Pierce SB, Morgan DO, Sara V, Smith MC, Roth RA. 1987 
The receptor for IGF-11 mediates an insulin-like response. EMBO J. 
6:3367-71. 
45. 
46. 
Vetter U, Zapf J, Heit W, et al. 1986 Human fetal and adult 
chondrocytes. Effect of IGF-I and -11, insulin and growth hormone 
on clonal growth. J Clin Invest. 77:1903-8. 
Kiess W, Greenstein LA, White RM, Lee L, Rechler MM, NissIey 
SP. 1987 Type II IGF receptor is present in rat serum. Proc Nat1 
Acad Sci USA. 84:7720-4. 
47. Gelato MC, Kiess W, Lee L, Malozowski S, RechIer MM, NissIey 
SP. 1988 The IGF-II/M6P receptor is present in monkey serum. J 
Clin Endocrinol Metab. 67:669-75. 
48. 
49. 
50. 
51. 
52. 
Causin C, Waheed A, Braulke T, et al. 1988 M6P/IGF-II binding 
proteins in human serum and urine. Biochem J. 252:795-9. 
Claimont KB, Czech MP. 1991 Extracellular release as the major 
degradative pathway of the IGF-II/M6P receptor. J Biol Chem. 
266:12131-4. 
Sklar M, Kiess W, Thomas CL, Nissley SP. 1989 Developmental 
expression of the tissue insulin-like growth factor-II/mannose-6- 
phosphate receptor in the rat. J Biol Chem. 264:16733-8. 
Hey AW, Browne CA, Thorburn GD. 1987 Fetal sheep serum 
contains a high molecular weight IGF binding protein that is acid 
stable and specific for IGF-11. Endocrinology. 121:1975-84. 
Laemmli UK. 1970 Cleavage of structural proteins during the 
 at UBM Klinikum Innenstadt on November 14, 2008 jcem.endojournals.orgDownloaded from 
IGF-II/MGP RECEPTOR IN MULTIPLE HUMAN TISSUES 
assembly of the head of bacteriophage T4. Nature. 227:680. 
53. Hossenlopp P, Seurin D, Degovia-Quinson B, Hardouin S, Binoux 
M. 1986 Analysis of serum insulin like growth factor binding 
proteins using Western blotting: use of the method for titration of 
the binding proteins and competitive binding studies. Anal Biochem. 
154:138-43. 
54. Nissley SP, Kiess W, Sklar MM. 1991 The IGF-ll/mannose-6- 
phosphate receptor. In: LeRoith D, ed. IGFs: molecular and cellular 
aspects. Boca Raton, FL: CRC Press. 
55. Taylor JE, Scott CD, Baxter RC. 1987 Comparison of receptors for 
insulin-like growth factor II from various rat tissues. J. Endocrinol. 
11535. 
56. MacDonald RG, Czech MP. 1985 Biosynthesis and processing of 
the type II insulin-like growth factor receptor in H-35 hepatoma 
cells. J Biol Chem. 260:11357-65. 
57. Kiess W, Greenstein LA, Lee L, Thomas C, Nissley SP. 1991 
Biosynthesis of the IGF-II/M6P receptor in rat C6 glial cells: the role 
of N-linked glycosylation in binding of IGF-II to the receptor. Mol 
Endocrinol. 5:281-91. 
 at UBM Klinikum Innenstadt on November 14, 2008 jcem.endojournals.orgDownloaded from 
